ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.

IKT Inhibikase Therapeutics Inc

1,39
0,05 (3,73%)
04 Mai 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Inhibikase Therapeutics Inc IKT NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
0,05 3,73% 1,39 06:00:10
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
1,38 1,3304 1,51 1,39 1,34
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
18.4.202422:30GLOBEInhibikase Therapeutics Issues Letter to Shareholders and..
03.4.202414:05GLOBEInhibikase Therapeutics Announces Pre-IND Meeting with the..
27.3.202421:15GLOBEInhibikase Therapeutics Reports Fourth Quarter and Full Year..
07.3.202414:30GLOBEInhibikase Therapeutics to Provide Trial Update for..
28.2.202422:05GLOBEInhibikase Therapeutics Announces Full Outcomes of its..
07.2.202413:59EDGAR2Form 8-K - Current report
07.2.202413:55GLOBEInhibikase Therapeutics Announces Preliminary Outcomes of..
01.2.202422:49EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
01.2.202422:09EDGAR2Form 8-K - Current report
29.1.202415:05GLOBEInhibikase Therapeutics Announces Publication Highlighting..
16.1.202422:31EDGAR2Form 8-K - Current report
16.1.202422:05GLOBEInhibikase Therapeutics Announces Planned Retirement of..
19.12.202314:30GLOBEInhibikase Therapeutics Issues Letter to Shareholders and..
04.12.202314:35GLOBEInhibikase Therapeutics Granted Pre-NDA Meeting with the FDA..
14.11.202322:30GLOBEInhibikase Therapeutics Reports Third Quarter Financial..
07.11.202315:28GLOBECorrecting & Replacing -- Inhibikase Therapeutics to Report..
07.11.202314:00GLOBEInhibikase Therapeutics to Report Second Quarter Financial..
16.10.202323:24EDGAR2Form 10-K/A - Annual report [Section 13 and 15(d), not S-K..
16.10.202313:00GLOBEInhibikase Therapeutics Highlights Unblinded Functional..
04.10.202314:30GLOBEInhibikase Therapeutics Receives FDA Orphan Drug Designation..
20.9.202317:23EDGAR2Form 8-K - Current report
24.8.202314:30PRNUSInhibikase Therapeutics Announces Development of Novel..
22.8.202314:05PRNUSInhibikase Therapeutics to Present at the International..
21.8.202314:30PRNUSInhibikase Therapeutics Initiates Development of Second..
17.8.202314:30PRNUSInhibikase Therapeutics Announces Completion of the 501..
14.8.202322:20PRNUSInhibikase Therapeutics Reports Second Quarter Financial..
14.8.202322:07EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07.8.202314:05PRNUSInhibikase Therapeutics to Report Second Quarter Financial..
17.7.202323:29EDGAR2Form 8-K - Current report
17.7.202322:05PRNUSInhibikase Therapeutics Regains Compliance with Nasdaq..
06.7.202303:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.7.202303:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29.6.202318:15EDGAR2Form 8-K - Current report
29.6.202315:29PRNUSInhibikase Therapeutics Announces a 1-for-6 Reverse Stock..
22.6.202314:05PRNUSInhibikase Therapeutics Announces Selection of the..
21.6.202314:05PRNUSInhibikase Therapeutics Initiates Medical and Patient..
30.5.202314:05PRNUSInhibikase Therapeutics to Present at the LD Micro..
16.5.202313:45PRNUSInhibikase Therapeutics Announces Dosing of First Patient in..
15.5.202314:30PRNUSInhibikase Therapeutics Reports First Quarter Financial..
08.5.202314:05PRNUSInhibikase Therapeutics to Report First Quarter Financial..

Kürzlich von Ihnen besucht

Delayed Upgrade Clock